Corcept Therapeutics IncorporatedCORTNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank93
3Y CAGR+34.1%
5Y CAGR+64.8%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+34.1%/yr
vs -4.7%/yr prior
5Y CAGR
+64.8%/yr
Recent deceleration
Acceleration
+38.8pp
Accelerating
Percentile
P93
Near historical high
vs 5Y Ago
12.1x
Strong expansion
Streak
2 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2025 | 60.08% |
| 2024 | 52.13% |
| 2023 | 20.55% |
| 2022 | 24.92% |
| 2021 | 16.17% |
| 2020 | 4.95% |
| 2019 | 23.46% |
| 2018 | 30.24% |
| 2017 | 37.97% |
| 2016 | 22.44% |